Rafael (RFL) Stock Price, News & Analysis

Company Overview

Rafael Holdings, Inc. (NYSE:RFL) is a diversified holding company with interests in biotechnology and commercial real estate. Through its life sciences operations, the company has focused on developing potential treatments for cancer and other serious diseases, including therapies designed to target the metabolism of cancer cells.

Rafael’s biotechnology activities have been conducted primarily through Rafael Pharmaceuticals, which has researched investigational drug candidates such as devimistat (also known as CPI-613). The company’s pharmaceutical programs are subject to clinical, regulatory and commercial uncertainties, and products under development may not receive regulatory approval.

The company also owns and manages commercial real estate assets, with a significant portion of its real estate interests located in Israel. Rafael Holdings was formed through the separation of certain businesses from IDT Corporation. Howard S. Jonas, the founder of IDT Corporation, has been closely associated with Rafael Holdings’ leadership and strategic direction.

Key Stats

• Today's Range: $1.18 to $1.30
• 50-Day Range: $1.18 to $2.60
• 52-Week Range: $1.12 to $3.96
• Volume: 45,484 shs
• Average Volume: N/A
• Market Capitalization: $66.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Rafael Stock Analysis - MarketRank™

Rafael scored higher than 14% of companies evaluated by MarketBeat, and ranked 851st out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Rafael has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Rafael has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Rafael is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rafael is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.00% of the float of Rafael has been sold short.

Short Interest Ratio / Days to Cover

Rafael has a short interest ratio ("days to cover") of 2.72, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rafael has recently decreased by 55.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rafael does not currently pay a dividend.

Dividend Growth

Rafael does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.33

News Sentiment

Rafael has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Rafael this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added Rafael to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rafael insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.90% of the stock of Rafael is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.30% of the stock of Rafael is held by institutions.

Company Calendar

• Last Earnings: 10/29/2025
• Today: 10/27/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 7/31/2027

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:RFL
• CIK: 1713863
• Web: www.rafaelholdings.com
• Phone: (212) 658-1450
• Fax: N/A
• Employees: 23
• Year Founded: 2000

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $980 thousand
• Price / Sales: 67.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 52,000,000
• Free Float: 34,892,000
• Market Cap: $66.61 million
• Optionable: Optionable
• Beta: 0.35